TII
Technology Innovation Institute (TII), the applied research pillar of Advanced Technology Research Council (ATRC), today announced the formation of a board of advisors at Cryptography Research Centre (CRC). The new board of advisors comprises global experts in the field of cryptography.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201214005303/en/
The appointments follow a series of rapid announcements at Technology Innovation Institute since the first Advanced Technology Research Council board meeting in August 2020.
CRC is one of the initial seven dedicated centres at TII and it is also one of the few global centres bringing together theoretical and applied cryptographers in a research-oriented setting. The cryptographers collaborate on breakthrough research projects that lead to innovative outcomes in cryptography. Spanning fields from post quantum cryptography (PQC), lightweight cryptography, cryptanalysis, cryptographic protocols, hardware-based cryptography, confidential computing, amongst others, the distinguished board of advisors will guide efforts to develop breakthrough technologies for global impact, reinforcing the UAE’s position as a global hub for innovation and R&D.
The Board of Advisors includes: Prof Joan Daemen , Professor of Symmetric Cryptography at Radboud University in The Netherlands, who co-designed the Rijndael cipher that was selected as the Advanced Encryption Standard (AES) and is also one of the co-designers of the Keccak (SHA-3) cryptographic algorithm; Prof Lejla Batina , Professor of Hardware Cryptography at Radboud University, whose expertise is in applied cryptography and embedded systems security; Dr Guido Bertoni , CEO of Security Pattern, Italy, whose research areas include cryptographic algorithms, hardware-based cryptography, applied cryptography and embedded systems security. He is also a co-designer of the Keccak (SHA-3) cryptographic algorithm. Prof. Carlos Aguilar , Professor of ISAE SUPAERO in Toulouse University, France, a post quantum cryptographer and expert in secure cryptographic implementations and computational theory; Prof. Damien Stehlé , Professor in Computer Science at École Normale Supérieure de Lyon, France, whose focus areas are post quantum cryptography, computational theory and complex algebra; and Prof. Tim Güneysu, Professor of Security Engineering at Ruhr-University Bochum, Germany, who is an expert in secure hardware implementations, cloud cryptographic schemes and secure engineering.
CRC currently employs and collaborates with scientists in multiple crucial fields of cryptography. The experts are engaged in the full spectrum of fundamental and applied cryptography and cryptanalysis research.
Speaking on the board appointments, Dr Najwa Aaraj, Chief Researcher at CRC, said: “The success of any scientific and research-focused entity is led by its board of advisors as they support in setting the vision. By bringing together renowned experts, we are connecting global expertise in the field of cryptography.”
Dr Aaraj added: “Through the research undertaken at the Cryptography Research Centre, we are confident that Abu Dhabi and the UAE will pioneer breakthrough technologies that ensure even greater enhancements in high-priority cryptographic areas.”
TII is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The Institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem in Abu Dhabi and the UAE. The Institute reinforces Abu Dhabi and the UAE’s status as a global hub for innovation and contributes to the broader development of the knowledge-based economy.
To know more about Cryptography Research Centre (CRC):
tii.ae/cryptographytii.ae/cryptography
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005303/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
